Edition:
United States

Manas Mishra

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

Oct 16 2020

Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. | Video

Walgreens promises return to profit growth as COVID-19 impact eases

Oct 15 2020

Walgreens Boots Alliance Inc on Thursday forecast a return to growth in profit next year, pinning hopes on shoppers coming back to its stores in the second half of the year after a safe and effective coronavirus vaccine is developed.

J&J says review of illness that led to pause of coronavirus vaccine trial could take days

Oct 13 2020

Johnson & Johnson said on Tuesday it would take a few days at least to hear from a safety monitoring panel about its review of the company's late-stage COVID-19 vaccine trial after announcing that the large study had been paused due to an unexplained illness in one participant. | Video

J&J says review of illness that led to coronavirus vaccine trial pause could take days

Oct 13 2020

Johnson & Johnson said on Tuesday it would take at least a few days for an independent safety panel to evaluate an unexplained illness of a study participant that led to a pause in the company's COVID-19 vaccine trial. | Video

U.S. expects over 1 million COVID-19 antibody doses from Regeneron, Lilly in 2020

Oct 09 2020

NEW YORK The U.S. government expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his illness, according to a top U.S. health official on Friday.

Eli Lilly applies for emergency use of antibody drug for COVID-19

Oct 07 2020

Eli Lilly and Co on Wednesday said it applied for U.S. emergency use authorization (EUA) for its experimental COVID-19 antibody treatment and plans to pursue a similar approval for a dual antibody therapy next month after it produced promising data.

U.S. FDA safety guidelines likely to push COVID-19 vaccine authorization past election

Oct 06 2020

The U.S. Food and Drug Administration told coronavirus vaccine developers on Tuesday it wants at least two months of safety data before authorizing emergency use, a requirement that would likely push any U.S. vaccine availability past the Nov. 3 presidential election.

U.S. CDC takes down coronavirus airborne transmission guidance

Sep 21 2020

The U.S. Centers for Disease Control and Prevention (CDC) on Monday took down its guidance warning on possible airborne transmission of the novel coronavirus, saying that the draft recommendation was posted in error. | Video

World News